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Abstract
PURPOSE In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly
improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in
patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death
ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an
updated OS and tolerability analysis, including analyses adjusting for potential bias introduced by crossover
from chemotherapy to pembrolizumab.
PATIENTS AND METHODS Patients were randomly assigned to pembrolizumab 200 mg every 3 weeks
(for up to 2 years) or investigator's choice of platinum-based chemotherapy (four to six cycles). Patients
assigned to chemotherapy could cross over to pembrolizumab upon meeting eligibility criteria. The primary
end point was progression-free survival; OS was an important key secondary end point. Crossover adjustment
analysis was done using the following three methods: simplified two-stage method, rank-preserving structural
failure time, and inverse probability of censoring weighting.
RESULTS Three hundred five patients were randomly assigned (pembrolizumab, n = 154; chemotherapy, n =
151). At data cutoff ( July 10, 2017; median follow-up, 25.2 months), 73 patients in the pembrolizumab arm
and 96 in the chemotherapy arm had died. Median OS was 30.0 months (95% CI, 18.3 months to not
reached) with pembrolizumab and 14.2 months (95% CI, 9.8 to 19.0 months) with chemotherapy (hazard
ratio, 0.63; 95% CI, 0.47 to 0.86). Eighty-two patients assigned to chemotherapy crossed over on study to
receive pembrolizumab. When adjusted for crossover using the two-stage method, the hazard ratio for OS for
pembrolizumab versus chemotherapy was 0.49 (95% CI, 0.34 to 0.69); results using rank-preserving
structural failure time and inverse probability of censoring weighting were similar. Treatment-related grade 3
to 5 adverse events were less frequent with pembrolizumab compared with chemotherapy (31.2% v 53.3%,
respectively).
CONCLUSION With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate
an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/
ALK aberrations, despite crossover from the control arm to pembrolizumab as subsequent therapy.
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abstract
PURPOSE In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved
progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with
previously untreated advanced non–small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor
proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability
analysis, including analyses adjusting for potential bias introduced by crossover from chemotherapy to
pembrolizumab.
PATIENTS AND METHODS Patients were randomly assigned to pembrolizumab 200 mg every 3 weeks (for up to
2 years) or investigator’s choice of platinum-based chemotherapy (four to six cycles). Patients assigned to
chemotherapy could cross over to pembrolizumab upon meeting eligibility criteria. The primary end point was
progression-free survival; OS was an important key secondary end point. Crossover adjustment analysis was
done using the following three methods: simplified two-stage method, rank-preserving structural failure time,
and inverse probability of censoring weighting.
RESULTS Three hundred five patients were randomly assigned (pembrolizumab, n = 154; chemotherapy, n =
151). At data cutoff (July 10, 2017; median follow-up, 25.2 months), 73 patients in the pembrolizumab arm and
96 in the chemotherapy arm had died. Median OS was 30.0 months (95% CI, 18.3 months to not reached) with
pembrolizumab and 14.2 months (95% CI, 9.8 to 19.0 months) with chemotherapy (hazard ratio, 0.63; 95% CI,
0.47 to 0.86). Eighty-two patients assigned to chemotherapy crossed over on study to receive pembrolizumab.
When adjusted for crossover using the two-stage method, the hazard ratio for OS for pembrolizumab versus
chemotherapy was 0.49 (95% CI, 0.34 to 0.69); results using rank-preserving structural failure time and inverse
probability of censoring weighting were similar. Treatment-related grade 3 to 5 adverse events were less frequent
with pembrolizumab compared with chemotherapy (31.2% v 53.3%, respectively).
CONCLUSIONWith prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS
benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aber-
rations, despite crossover from the control arm to pembrolizumab as subsequent therapy.
J Clin Oncol 37:537-546. © 2019 by American Society of Clinical Oncology
INTRODUCTION
KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738)
is an international, randomized, open-label, phase III
study of pembrolizumabmonotherapy versus platinum-
based chemotherapy in patients with previously
untreated advanced non–small-cell lung cancer
(NSCLC) with programmed death ligand 1 (PD-L1)
tumor proportion score (TPS) of 50% or greater and
without EGFR mutation or ALK translocation.1 At the
second preplanned interim analysis (median follow-
up, 11.2 months), pembrolizumab was associated
with significantly improved progression-free survival
(PFS; hazard ratio [HR], 0.50; 95% CI, 0.37 to 0.68;
one-sided P , .001) and overall survival (OS; HR,
0.60; 95% CI, 0.41 to 0.89; one-sided P = .005).
Median OS was not reached (NR) in either arm.
Importantly, pembrolizumab was generally well tol-
erated. On the basis of these results, the independent
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data and safety monitoring committee recommended the
trial be stopped early to allow for use of pembrolizumab
in patients randomly assigned to chemotherapy. The
improvement in OS occurred despite the study design
allowing patients randomly assigned to chemotherapy to
cross over to pembrolizumab. The observed treatment
effect was potentially attenuated because many patients
participated in this crossover.
We report an updated analysis of OS and other efficacy and
safety outcomes after a median follow-up of 25.2 months.
In addition, we describe outcomes among patients who
crossed over from chemotherapy to pembrolizumab per
protocol and analyses that adjusted for potential bias
introduced by treatment crossover.
PATIENTS AND METHODS
Patients
As described previously,1 adult patients eligible for en-
rollment had untreated stage IV NSCLC with PD-L1 TPS
of 50% or greater, Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 1 or lower, measurable
disease per Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1,2 and life expectancy of 3 months or
longer. Patients were excluded if they had sensitizing EGFR
mutations, ALK translocations, untreated brain metastases,
or active autoimmune disease requiring systemic therapy
or were receiving systemic glucocorticoids or other immu-
nosuppressive therapy.
Patients provided written informed consent. The protocol
(MK-3475-024-06) was approved by the institutional
review boards or independent ethics committees of the
participating institutions, and the trial was conducted in
accordance with Good Clinical Practice guidelines and the
Declaration of Helsinki.
Study Design
Eligible patients were randomly assigned (1:1; stratified
by ECOG PS of 0 v 1, squamous v nonsquamous histology,
East Asian v non–East Asian enrollment site) to receive
intravenous pembrolizumab (200 mg every 3 weeks) for 35
cycles (2 years) or investigator’s choice of platinum-based
chemotherapy (carboplatin plus pemetrexed, cisplatin plus
pemetrexed, carboplatin plus gemcitabine, cisplatin plus
gemcitabine, or carboplatin plus paclitaxel; pemetrexed-
containing regimens were only permitted for patients with
nonsquamous disease) for four to six cycles, in the absence
of radiologic disease progression (per RECIST), treatment-
related adverse events (AEs) of unacceptable severity, or
patient withdrawal. Pemetrexed-containing chemotherapy
regimens and subsequent use of pemetrexed as main-
tenance therapy were permitted for patients with non-
squamous tumors. Patients assigned to chemotherapy
could cross over to pembrolizumab (starting 30 days or
more after last chemotherapy dose) if safety eligibility cri-
teria were met; before the second interim analysis that
revealed superiority, only patients with progressive disease
confirmed by blinded, independent, central radiology
review were eligible. The protocol did not include pre-
planned crossover from pembrolizumab to chemotherapy
or postprogression treatment guidelines for pembrolizumab
recipients. Patients in either arm who were clinically stable
and considered by the investigator to be deriving clinical
benefit could continue therapy after disease progression.
The primary end point was PFS (time since random
assignment to disease progression or death from any
cause, whichever occurred first). OS (time since random
assignment to death from any cause) was an important
secondary end point; objective response rate (ORR; con-
firmed complete and partial responses) and safety were
other secondary end points. Exploratory end points inclu-
ded duration of response (DOR), patient-reported out-
comes,3 and time since random assignment to objective
tumor progression on next-line treatment or death from any
cause, whichever occurred first.4
Assessments
As described previously,1 PD-L1 expression was assessed
in formalin-fixed tumor samples (from core-needle or
excisional biopsy or tissue resected at time of diagnosis of
metastatic disease) using the PD-L1 IHC 22C3 pharmDx
assay (Agilent, Santa Clara, CA).5,6 Imaging studies were
performed every 9 weeks. Response was assessed per
RECIST version 1.1 by blinded, independent, central
radiology review (stopped after the second interim analysis
[protocol amendment 6]) and by investigator assessment.
Patients were contacted every 2 months during follow-up to
evaluate OS. All AEs occurring from random assignment
until 30 days after the last dose of study treatment (90 days
for serious AEs) were graded per the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 4.0. The sponsor reviewed all AEs and condensed
several AE preferred terms that suggested an immune-
mediated etiology for specific categories, regardless of
investigator-assessed attribution of the event.
Statistical Analysis
The final protocol-specified OS analysis was to occur after
approximately 170 patients had died, providing approx-
imately 75% power to observe an HR of less than 1,
assuming approximately 70% of the patients in the che-
motherapy arm crossed over to pembrolizumab. Because
OS benefit was confirmed at the second interim analysis
(data cutoff, May 9, 2016; 108 of 305 patients had died),
this final analysis was not subjected to multiplicity control.
Efficacy was assessed in the intent-to-treat population (all
randomly assigned patients), and safety was assessed in
the as-treated population (patients who were randomly
assigned and received one or more doses of study treat-
ment, analyzed by treatment received). The Kaplan-Meier
method was used to estimate OS, with censoring of data for
patients alive or lost to follow-up at time of last contact.
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Between-group difference in OS was assessed using a
stratified log-rank test. HRs and associated 95% CIs were
assessed using a stratified Cox proportional hazards model
with Efron’s method of handling ties. Randomization
stratification factors were applied to the stratified log-rank
and Cox models. After crossover to pembrolizumab, DOR
was summarized using the Kaplan-Meier method for
patients with confirmed complete or partial responses in
this phase.
Additional analyses for OS, intended to complement the
intent-to-treat analysis, were conducted to estimate the
treatment difference between pembrolizumab and che-
motherapy adjusted for crossover. The following three
statistical methods were applied: the simplified two-stage,
rank-preserving structural failure time (RPSFT), and
inverse probability of censoring weighting (IPCW) methods.
In stage 1 of the two-stage model (described by Latimer
et al7,8), a log-normal parametric survival model accounting
for important covariates was developed to estimate the
effect of crossover in the chemotherapy arm (acceleration
factor) that was then used to adjust survival times for
patients who crossed over to pembrolizumab. Patients were
eligible for inclusion in stage 1 if they met the following
criteria consistent with the clinical criteria for crossover
before the second interim analysis: centrally verified dis-
ease progression, no discontinuation of chemotherapy for
any reason other than progressive disease, ECOG PS of 0 or
1 at progression, survival of 30 days or longer after ces-
sation of chemotherapy, and initiation of pembrolizumab
30 days or more after last chemotherapy dose. In the
second stage, observed survival times in the pem-
brolizumab arm were compared with adjusted survival
times in the chemotherapy arm and analyzed with a
stratified proportional hazards model. Bootstrapping was
used to estimate the 95% CI of the acceleration factor and
treatment effect HR.
In the RPSFT model,9,10 survival times of patients in the
chemotherapy arm who crossed over were adjusted
multiplicatively by an acceleration factor determined by
G-estimation to estimate the expected survival time if
patients had not crossed over. Survival times of all patients
randomly assigned to chemotherapy were recensored to
maintain the assumption of noninformative censoring.
Observed survival times in the pembrolizumab arm were
compared with adjusted survival times in the chemotherapy
arm using a Cox proportional hazards model. Bootstrapping
was used to estimate the 95% CIs of the HR.
The IPCW method addressed treatment crossover by
introducing artificial censoring at time of crossover for each
patient. To adjust for potential confounding from artificial
censoring, weights were calculated for observations before
crossover according to patient baseline and time-varying
demographic and disease-related characteristics (as
described by Latimer et al11). These were then used in a
weighted Cox proportional hazards model to estimate the
HR of pembrolizumab versus chemotherapy; the 95% CI
was estimated by bootstrapping.
RESULTS
Patients and Treatment
KEYNOTE-024 included 305 randomly assigned patients
(pembrolizumab, n = 154; chemotherapy, n = 151)
from 142 sites in 16 countries; all except one patient in
the chemotherapy arm received study treatment (Fig 1).
At data cutoff (July 10, 2017), median follow-up was
25.2 months (range, 20.4 to 33.7 months); 235 treated
patients across both arms had discontinued initially
assigned study treatment. Median treatment duration
was 7.9 months (range, 1 day to 28.8 months) in the
pembrolizumab arm and 3.5 months (range, 1 day to
30.5 months) in the chemotherapy arm. In the che-
motherapy arm, 82 patients had crossed over to pem-
brolizumab on study; 15 additional patients received
anti–PD-1 treatment outside of the crossover (second line,
n = 12; third or later line, n = 3), for a crossover rate of
64.2% (97 of 151 patients) in the intent-to-treat population
and an effective crossover rate of 65.1% (97 of 149
patients) excluding patients remaining on therapy. Median
treatment duration for patients receiving on-study pem-
brolizumab crossover was 3.9 months (range, 1 day to
23.7 months; Fig 1). In the pembrolizumab arm, 56
patients went on to receive one or more subsequent
oncologic treatments, including surgery, radiation therapy,
chemotherapy, and immunotherapy (pembrolizumab,
n = 3; nivolumab, n = 5), after discontinuation. Patient
demographic and baseline clinical characteristics were
generally well balanced between the arms (Table 1).
Efficacy Outcomes
At data cutoff, 169 patients had died (pembrolizumab, n =
73; chemotherapy, n = 96). Median OS was 30.0 months
(95% CI, 18.3 months to NR) in the pembrolizumab arm
and 14.2 months (95% CI, 9.8 to 19.0 months) in the
chemotherapy arm (HR, 0.63; 95% CI, 0.47 to 0.86; one-
sided nominal P = .002). Kaplan-Meier estimates of OS at
12 months for pembrolizumab and chemotherapy were
70.3% (95% CI, 62.3% to 76.9%) and 54.8% (95%
CI, 46.4% to 62.4%), respectively, with corresponding
24-month rates of 51.5% (95% CI, 43.0% to 59.3%) and
34.5% (95% CI, 26.7% to 42.4%; Fig 2A), respectively. An
OS benefit for pembrolizumab compared with chemo-
therapy was observed in all subgroups evaluated (Fig 2B).
Efficacy Outcomes in the On-Study Crossover Phase
Baseline characteristics for the 82 patients who crossed
over to on-study pembrolizumab were similar to those for
the overall study population (Appendix Table A1, online
only). Seventeen of 82 patients who crossed over had an
objective response per investigator assessment (ORR,
20.7%; 95% CI, 12.6% to 31.1%). Nineteen patients
(23.2%) had stable disease. Median time to response was
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2.0 months (range, 1.1 to 8.4 months), and median DOR
was NR (range, 2.1 [ongoing] to 22.9 [ongoing] months)
after on-study crossover (Fig 3).
Crossover Adjustment
Seventy-seven patients randomly assigned to chemotherapy
met the prespecified criteria for inclusion in stage 1 of the
two-stage analysis (centrally verified progression, no dis-
continuation of chemotherapy other than for progressive
disease, ECOG PS of 0 or 1 at time of progression, and
survival of 30 days or more after cessation of chemotherapy).
This is less than the number of patients who qualified for on-
study crossover (n = 82), as described earlier, as a result of
the requirement for disease progression. Sixty-three of these
77 patients crossed over to pembrolizumab on study; 14 of
these patients did not, although four patients received
anti–PD-1 treatment outside the study (pembrolizumab,
n = 2; nivolumab, n = 2). The estimated acceleration factor
was 4.00 (95% CI, 1.59 to 11.30), indicating the survival
period after disease progression was reduced by 75% in the
chemotherapy arm versus unadjusted outcomes, resulting
in an adjusted median OS of 8.7 months (95% CI, 7.3 to
11.5 months). In stage 2, the adjusted HR for the adjusted
OS in the chemotherapy arm versus the observed OS in the
pembrolizumab arm was 0.49 (95% CI, 0.34 to 0.69; Fig
4). Similar results were obtained with the RPSFT and IPCW
methods; RPSFT-adjusted median OS was 11.8 months
(95% CI, 8.7 months to NR; adjusted HR, 0.52; 95% CI,
0.33 to 0.75) and IPCW-adjusted median OS was 11.8
months (95% CI, 8.7 to 21.3 months; adjusted HR, 0.52;
95% CI, 0.33 to 0.80).
Toxicity
During treatment with initially assigned therapy, treatment-
related AEs occurred in 76.6% (grade 3 to 5, 31.2%) and
90.0% (grade 3 to 5, 53.3%) of patients in the pem-
brolizumab and chemotherapy arms, respectively (Table 2).
Incidences of serious treatment-related AEs (22.7% and
20.7% in the pembrolizumab and chemotherapy arms,
respectively) and treatment discontinuation as a result of
treatment-related AEs (13.6% and 10.7% in the pem-
brolizumab and chemotherapy arms, respectively) were
similar between the arms. There were five treatment-related
fatal AEs (pembrolizumab, n = 2; chemotherapy, n = 3;
four were previously reported1 [pembrolizumab: sudden death
of unknown cause; chemotherapy: pulmonary sepsis,
pulmonary alveolar hemorrhage, and death of unknown
cause]). With longer follow-up in this analysis, there was
one additional death in the pembrolizumab arm (pneu-
monitis occurring on day 181 of pembrolizumab treatment
with significant delay in start of immunosuppressive therapy).
The most frequent treatment-related AEs were diarrhea
(16.2%) and fatigue (14.3%) in the pembrolizumab arm
and anemia (44.0%) and nausea (43.3%) in the chemo-
therapy arm (Table 2). In the pembrolizumab arm, the most
Patients randomly assigned 
(N = 305)
Chemotherapy
Patients assigned
Patients treated
   Median treatment duration,
   3.5 months (range, 1 day to 30.5 months)
(n = 151)
(n = 150)
Treatment ongoing
Completed treatment
Discontinued
   Progressive disease*
   AEs
   Died
   Patient withdrew
   Physician decision
(n = 2)
(n = 27)
(n = 121)
(n = 76)
(n = 19)
(n = 9)
(n = 6)
(n = 11)
Pembrolizumab
Patients assigned
Patients treated
   Median treatment duration,
    7.9 months (range, 1 day to 28.8 months)
(n = 154)
(n = 154)
Treatment ongoing
Completed treatment
Discontinued
  Progressive disease*
  AEs
  Died
  Patient withdrew
  Complete response
  Physician decision
(n = 23)
(n = 17)
(n = 114)
(n = 67)
(n = 30)
(n = 7)
(n = 7)
(n = 2)
(n = 1)
Crossed over to pembrolizumab on study
  Median treatment duration,
                         3.9 months (range, 1 day to 23.7 months)
+
Received anti–PD-1 outside of crossover
   Received as second-line therapy
   Received as third-line or later therapy
(n = 15)
(n = 12)
(n = 3)
(n = 82)
FIG 1. Disposition of patients in the
study. (*) Includes patients with
clinical progression or progressive
disease. AEs, adverse events; PD-1,
programmed death 1.
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common grade 3 to 5 treatment-related AEs were diarrhea
(3.9%) and pneumonitis (3.2%). Immune-mediated AEs and
infusion reactions, regardless of relationship to treatment,
occurred in 33.8% (grade 3 to 5, 13.6%) and 5.3% (grade 3
to 5, 0.7%) of patients in the pembrolizumab and chemo-
therapy arms, respectively (Table 2).
During crossover, the rates of any grade, grade 3 to 5, and
serious treatment-related AEs were 61.0%, 9.8%, and
8.5%, respectively (discontinuation rate due to treatment-
related AEs, 6.1%). There were no grade 5 treatment-
related AEs during on-study crossover. Among crossover
patients, 16 (19.5%) developed an immune-mediated AE
and/or infusion reaction (hypothyroidism, 9.8%; hyper-
thyroidism, 6.1%; pneumonitis, 4.9%; adrenal insuffi-
ciency, 1.2%; and infusion reaction, 1.2%).
DISCUSSION
In this updated analysis of KEYNOTE-024, pembrolizumab
continues to show an OS benefit as first-line therapy for
advanced NSCLC with PD-L1 TPS of 50% or greater
compared with platinum-based chemotherapy (HR, 0.63;
95% CI, 0.47 to 0.86; nominal P = .002). The improvement
in OS first reported at the second interim analysis1 was
maintained despite significant crossover to pembrolizumab
in the chemotherapy arm, with a notable median OS of
30.0 months for patients randomly assigned to pem-
brolizumab compared with 14.2 months for patients in the
chemotherapy arm. This efficacy outcome is more favor-
able than that described in trials evaluating platinum-based
chemotherapy as first-line treatment of NSCLC.12 To our
knowledge, KEYNOTE-024 is the first study to show an
OS benefit with anti–PD-1 monotherapy compared with
platinum-based chemotherapy as first-line treatment in
patients with advanced NSCLC and has changed the
treatment paradigm of this disease.
With median exposure of 7.9 months in the pembrolizumab
arm at the time of analysis (more than double that in the
chemotherapy arm), pembrolizumab continues to dem-
onstrate a favorable safety profile. The incidence, severity,
and nature of AEs were consistent with those described
previously,1 with no evidence of cumulative toxicity with
longer exposure and no new safety signals when comparing
incidence of AEs during pembrolizumab treatment with
those among patients who received chemotherapy (not-
withstanding the longer treatment duration with initial
therapy in the pembrolizumab arm). In the updated
analysis, there was one additional fatal immune-mediated
AE as a result of pneumonitis. Although median time to the
first pneumonitis event was 100 days in the pembrolizumab
arm, this AE developed at day 181. Initially confused with
disease progression, immunosuppression was delayed
until after the patient underwent two separate biopsies.
Whereas at the second interim analysis 66 patients had
received pembrolizumab crossover therapy, at the time of
this analysis 82 patients had crossed over and 15 additional
patients had received subsequent anti–PD-1 therapy
(crossover rate, 64.2% in the intent-to-treat population;
effective crossover rate, 65.1% excluding patients remaining
on therapy). Outcomes in the crossover population are indi-
cative of treatment benefit for second-line pembrolizumab
monotherapy (ORR, 20.7%; median DOR, NR) and are
consistent with outcomes for patients with PD-L1 TPS of 50%
or greater in the phase III KEYNOTE-010 (ClinicalTrials.gov
identifier: NCT01905657) study of pembrolizumab versus
docetaxel in patients with previously treated NSCLC.13
The high rate of crossover in this study (reflecting both the
study design and decision of the data and safety monitoring
committee to stop the trial analysis early) and apparent
activity of pembrolizumab during the crossover period likely
attenuated the observed OS effect. We used three statistical
methods to adjust for the influence of crossover on OS, and
all three supported an HR more strongly favoring the
pembrolizumab arm. The two-stage model was preferred,
as a result of evidence of deviation from the common
TABLE 1. Patient Demographic and Baseline Disease Characteristics
Characteristic
Pembrolizumab
(n = 154)
Chemotherapy
(n = 151)
Median age, years (range) 64.5 (33-90) 66.0 (38-85)
Sex
Male 92 (59.7) 95 (62.9)
Female 62 (40.3) 56 (37.1)
ECOG PS score
0 54 (35.1) 53 (35.1)
1 99 (64.3) 98 (64.9)
2 1 (0.6) 0 (0)
Region of enrollment
East Asia 21 (13.6) 19 (12.6)
Non–East Asia 133 (86.4) 132 (87.4)
Histology
Squamous* 29 (18.8) 27 (17.9)
Nonsquamous† 125 (81.2) 124 (82.1)
Smoking status
Current 34 (22.1) 31 (20.5)
Former 115 (74.7) 101 (66.9)
Never 5 (3.2) 19 (12.6)
Treated brain metastases 18 (11.7) 10 (6.6)
Prior neoadjuvant therapy 3 (1.9) 1 (0.7)
Prior adjuvant therapy 6 (3.9) 3 (2.0)
NOTE. Data presented as No (%), unless otherwise noted.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance
status.
*Includes poorly differentiated squamous cell carcinoma (chemotherapy, n = 1).
†Includes adenosquamous (pembrolizumab, n = 2; chemotherapy, n = 2),
sarcomatoid (pembrolizumab, n = 3; chemotherapy, n = 2), and poorly
differentiated (pembrolizumab, n = 9; chemotherapy, n = 3) histologies.
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treatment effect assumed in RPSFT and because the IPCW
method is more prone to bias in the presence of relatively
small sample sizes.7,11 Overall, the crossover-adjusted
analyses complement the primary efficacy analysis and
reinforce the potential to improve outcomes with early use
of pembrolizumab as first-line treatment.
Given the OS and PFS benefits observed in KEYNOTE-024,
pembrolizumab remains the only checkpoint inhibitor
approved in the first-line setting as monotherapy for
patients with PD-L1 TPS of 50% or greater. Recently,
results from the KEYNOTE-042 (ClinicalTrials.gov identifier:
NCT02220894) study confirmed and extended those from
KEYNOTE-024 by demonstrating significantly improved OS
with pembrolizumab versus platinum-based chemotherapy
not only in treatment-naive patients with PD-L1 TPS of 50%
or greater (HR, 0.69; 95% CI, 0.56 to 0.85; P = .0003), but
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FIG 2. (A) Kaplan-Meier analysis and
(B) subgroup analysis of overall sur-
vival (OS). Vertical dotted line in
subgroup analysis represents hazard
ratio (HR) in the overall population.
(*) Nominal P value. ECOG PS,
Eastern Cooperative Oncology Group
performance status; NR, not reached;
PD-1, programmed death 1.
542 © 2019 by American Society of Clinical Oncology Volume 37, Issue 7
Reck et al
Downloaded from ascopubs.org by University of Glasgow Library on April 29, 2019 from 130.209.006.061
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
also in those with PD-L1 TPS of 20% or greater (HR, 0.77;
95% CI, 0.64 to 0.92; P = .002) and 1% or greater (HR, 0.81;
95%CI, 0.71 to 0.93; P= .0018).14 In contrast, administration
of nivolumab 3 mg/kg every 2 weeks in the CheckMate 026
(ClinicalTrials.gov identifier: NCT02041533) study did not
improve PFS or OS among patients with previously untreated
advanced NSCLC with PD-L1 expression of 5% or greater.15
Although cross-trial comparisons should be approached with
caution, different PD-L1 assays (with different anti–PD-L1
antibodies) and thresholds were used in CheckMate 026
relative to KEYNOTE-024 and KEYNOTE-042, which may, in
part, explain the opposing outcomes.16
Pembrolizumab with platinum chemotherapy has been
evaluated in several trials. In the randomized cohort G of
the phase I/II KEYNOTE-021 (ClinicalTrials.gov identifier:
NCT02039674) study, pembrolizumab plus carboplatin and
pemetrexed in patients with newly diagnosed, advanced,
nonsquamous NSCLC without EGFR/ALK alterations irre-
spective of PD-L1 TPS demonstrated improved ORR and PFS
compared with carboplatin and pemetrexed alone,17 leading
to approval in the United States. The phase III KEYNOTE-189
(ClinicalTrials.gov identifier: NCT 02578680) study evaluated
first-line pembrolizumab plus pemetrexed and platinum in
patients with nonsquamous metastatic NSCLC irrespective of
PD-L1 tumor expression and showed significant improvement
in OS (HR, 0.49; 95% CI, 0.38 to 0.64; P , .001) and PFS
(HR, 0.52; 95% CI, 0.43 to 0.64; P , .001) compared with
placebo plus chemotherapy.18 Pembrolizumab in combination
with carboplatin and paclitaxel or nab-paclitaxel resulted in
improved OS and PFS compared with placebo plus car-
boplatin and paclitaxel or nab-paclitaxel in patients with
squamous histology regardless of PD-L1 expression (OS HR,
0.64; 95% CI, 0.49 to 0.85; P , .001; PFS HR, 0.56; 95%
CI, 0.45 to 0.70; P , .001) in the phase III KEYNOTE-407
(ClinicalTrials.gov identifier: NCT02775435) study.19
Together with our current analyses, these data show
that for all patients with advanced NSCLC without EGFR/
ALK alterations, a first-line treatment regimen containing
pembrolizumab (either as monotherapy or in combination
with platinum chemotherapy) is available that can improve
OS compared with platinum doublet chemotherapy.
In addition, other anti–programmed death 1 or anti–PD-L1
antibodies have been evaluated in combination with
chemotherapy or immunotherapy in patients with NSCLC.
Atezolizumab with bevacizumab, carboplatin, and paclitaxel
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TABLE 2. Adverse Events in the As-Treated Population
Adverse Event
No. of Patients (%)
Pembrolizumab (n = 154) Chemotherapy (n = 150)
Treatment-related AEs†
Any grade 118 (76.6) 135 (90.0)
Grade 3-5 48 (31.2) 80 (53.3)
Serious 35 (22.7) 31 (20.7)
Led to discontinuation 21 (13.6) 16 (10.7)
Led to death 2 (1.3) 3 (2.0)
Treatment-related AEs occurring in $ 10% of patients in
either arm‡
Any Grade Grade 3 or 4* Any Grade Grade 3 or 4*
Diarrhea 25 (16.2) 6 (3.9) 21 (14.0) 2 (1.3)
Fatigue 22 (14.3) 3 (1.9) 43 (28.7) 5 (3.3)
Pyrexia 18 (11.7) 0 9 (6.0) 0
Pruritus 18 (11.7) 0 3 (2.0) 0
Rash 16 (10.4) 2 (1.3) 3 (2.0) 0
Nausea 15 (9.7) 0 65 (43.3) 3 (2.0)
Decreased appetite 15 (9.7) 0 39 (26.0) 4 (2.7)
Anemia 8 (5.2) 2 (1.3) 66 (44.0) 29 (19.3)
Constipation 6 (3.9) 0 17 (11.3) 0
Blood creatinine increased 5 (3.2) 0 16 (10.7) 0
Vomiting 4 (2.6) 0 30 (20.0) 0
Stomatitis 4 (2.6) 0 18 (12.0) 2 (1.3)
Neutropenia 1 (0.6) 0 33 (22.0) 20 (13.3)
Neutrophil count decreased 1 (0.6) 0 21 (14.0) 7 (4.7)
WBC count decreased 1 (0.6) 0 17 (11.3) 4 (2.7)
Dysgeusia 1 (0.6) 0 16 (10.7) 0
Platelet count decreased 0 0 18 (12.0) 10 (6.7)
Thrombocytopenia 0 0 16 (10.7) 8 (5.3)
AEs with possible immune etiology occurring in $ 0% of
patients
Any Grade Grade 3 or 4§ Any Grade Grade 3 or 4§
Any 52 (33.8) 20 (13.2) 8 (5.3) 1 (0.7)
Hypothyroidism 16 (10.4) 0 3 (2.0) 0
Pneumonitis 12 (7.8) 4 (2.6) 1 (0.7) 1 (0.7)
Hyperthyroidism 11 (7.1) 0 2 (1.3) 0
Infusion reactions 8 (5.2) 1 (0.6) 2 (1.3) 0
Severe skin reactions 8 (5.2) 8 (5.2) 0 0
Colitis 6 (3.9) 3 (1.9) 0 0
Thyroiditis 4 (2.6) 0 0 0
Myositis 3 (1.9) 0 0 0
Hepatitis 1 (0.6) 1 (0.6) 0 0
Hypophysitis 1 (0.6) 1 (0.6) 0 0
Nephritis 1 (0.6) 1 (0.6) 0 0
(continued on following page)
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improved OS (HR, 0.78; 95% CI, 0.64 to 0.96; P = .02) and
PFS (HR, 0.62; 95% CI, 0.52 to 0.74; P , .001) compared
with bevacizumab, carboplatin, and paclitaxel in patients with
nonsquamous histology,20 and atezolizumab with carboplatin
and nab-paclitaxel improved median PFS (HR, 0.715; 95%
CI, 0.603 to 0.848; P = .0001) but not OS (HR, 0.96; 95% CI,
0.78 to 1.18; P = .6931) compared with carboplatin plus nab-
paclitaxel in patients with squamous NSCLC.21 Nivolumab
with chemotherapy improved PFS compared with chemo-
therapy alone in patients whose tumors did not express PD-L1
(HR, 0.74; 95% CI, 0.58 to 0.94).22 Finally, nivolumab plus
ipilimumab demonstrated longer PFS compared with che-
motherapy (HR, 0.83; 95% CI, 0.72 to 0.96), particularly in
patients with high tumormutational burden (HR, 0.58; 97.5%
CI, 0.41 to 0.81).23 At present, tumor mutational burden does
not have a role in guiding treatment decisions, because an OS
benefit has not been shown.
In conclusion, in this updated analysis of KEYNOTE-024,
pembrolizumab continued to provide improved OS relative
to platinum-based chemotherapy, notwithstanding the high
rate of crossover. There was no evidence of cumulative
toxicity. These results support pembrolizumab mono-
therapy as a standard-of-care regimen for first-line treat-
ment of advanced NSCLC with PD-L1 TPS of 50% or
greater and without EGFR/ALK alterations.
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22927 Großhansdorf, Germany; e-mail: m.reck@lungenclinic.de.
PRIOR PRESENTATION
Presented, in part, at the International Association for the Study of Lung
Cancer 18th World Conference on Lung Cancer, Yokohama, Japan,
October 15-18, 2017, and the European Lung Cancer Congress, Geneva,
Switzerland, April 11-14, 2018.
SUPPORT
Supported by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc.,
Kenilworth, NJ.
AUTHOR’S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
AND DATA AVAILABILITY STATEMENT
Disclosures provided by the author and data availability statement (if
applicable) are available with this article at DOI https://doi.org/10.1200/
JCO.18.00149.
TABLE 2. Adverse Events in the As-Treated Population (continued)
Adverse Event
No. of Patients (%)
Pembrolizumab (n = 154) Chemotherapy (n = 150)
Pancreatitis 1 (0.6) 1 (0.6) 0 0
Type 1 diabetes 1 (0.6) 1 (0.6) 0 0
Uveitis 1 (0.6) 1 (0.6) 0 0
NOTE. The as-treated population included all patients who were randomly assigned and received one ormore doses of a trial treatment. Adverse events that
occurred during crossover from the chemotherapy arm to pembrolizumab are excluded.
Abbreviation: AEs, adverse events.
*Two grade 5 treatment-related adverse events occurred in the pembrolizumab arm (pneumonitis and sudden death) and three in the chemotherapy arm
(death, pulmonary sepsis, and pulmonary alveolar hemorrhage).
†Events were attributed to treatment by the investigator and are listed as indicated by the investigator on the case report form. Although decreased
neutrophil count and neutropeniamay reflect the same condition, they were listed by the investigators as two distinct events; this is also the case for decreased
platelet count and thrombocytopenia.
‡Events are listed in descending order of frequency in the total population.
§One grade 5 immune-mediated AE occurred in the pembrolizumab arm (pneumonitis).
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APPENDIX
TABLE A1. Demographic and Baseline Disease Characteristics Among Patients
Who Crossed Over to On-Study Pembrolizumab
Characteristic
No. of Crossover Patients
(n = 82)
Median age, years (range) 65.0 (40-83)
Sex
Male 47 (57.3)
Female 35 (42.7)
ECOG PS score
0 37 (45.1)
1 45 (54.9)
Region of enrollment
East Asia 10 (12.2)
Non–East Asia 72 (87.8)
Histology
Squamous 18 (22.0)
Nonsquamous* 64 (78.0)
Smoking status
Current 15 (18.3)
Former 52 (63.4)
Never 15 (18.3)
Treated brain metastases 3 (3.7)
Prior neoadjuvant therapy 0
Prior adjuvant therapy 3 (3.7)
NOTE. Data presented as No (%), unless otherwise noted.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance
status.
*Includes adenosquamous (n = 1), sarcomatoid (n = 2), and poorly differentiated
(n = 1) histologies.
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